Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

Figures & data

Figure 1 Percentage changes in BMD of lumbar spine in GIO patients treated with either daily risedronate or annual zoledronic acid (HORIZON).³⁷

Abbreviations: BMD, bone mineral density; GIO, glucocorticoid-induced osteoporosis.

ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet200937396711253126319362675

 PubMed Web of Science ®Google Scholar